Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.
About
Signadori Bio SAS is a preclinical-stage biopharmaceutical company focused on developing an innovative immunotherapy platform. Their approach utilizes in vivo engineered monocytes, designed to be an off-the-shelf solution for treating solid tumors. The company aims to advance novel therapeutic strategies in oncology.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Signadori Bio do?
Signadori Bio SAS is a preclinical-stage biopharmaceutical company focused on developing an innovative immunotherapy platform. Their approach utilizes in vivo engineered monocytes, designed to be an off-the-shelf solution for treating solid tumors. The company aims to advance novel therapeutic strategies in oncology.
How much funding has Signadori Bio raised?
Signadori Bio has raised a total of $12M in funding. The most recent round on record is Seed Extension.
Where is Signadori Bio headquartered?
Signadori Bio is headquartered in Paris, France.
When was Signadori Bio founded?
Signadori Bio was founded in 2025.
What industry does Signadori Bio operate in?
Signadori Bio operates in Biotechnology, Pharmaceuticals, Oncology, Immunotherapy, Biopharmaceuticals, Drug Discovery.